Disclosures for "The rs10191329 Risk Allele is Associated with Retinal Layer Thinning in Multiple Sclerosis"
-
Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene-BMS. Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi Genzyme.
-
Author has nothing to disclose
-
Dr. Föttinger has nothing to disclose.
-
Dr. Koenig has nothing to disclose.
-
Dr. Krenn has nothing to disclose.
-
Markus Ponleitner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus Therapeutics, Inc.. Markus Ponleitner has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amicus Therapeutics Inc.. Markus Ponleitner has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Markus Ponleitner has received research support from European Academy of Neurology.
-
Dr. Hegen has nothing to disclose.
-
Dr. Pemp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chiesi. Dr. Pemp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chiesi. Dr. Pemp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GenSight. The institution of Dr. Pemp has received research support from Chiesi.
-
Prof. Berger has received personal compensation in the range of $10,000-$49,999 for serving as a speaker at scientific meetings and participant of local and international advisory boards with various companies producing and markerting treatments for multiple sclerosis (Almirall, Biogen, Biologix, Bionorica, Celgene-BMS, Merck, Novartis, Roche, Sanofi-Genzyme, TG Therapeutics, UCB).